SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

AGM & Q1 IMS

9 Feb 2018 07:00

RNS Number : 3712E
Victrex PLC
09 February 2018
 
 

 

9 February 2018

Victrex plc

AGM and Q1 Interim Management Statement

'A strong start to 2018'

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its first quarter (Q1) Interim Management Statement ahead of its Annual General Meeting (AGM) being held today.

Victrex made a strong start to its 2018 financial year, with a continuing positive performance in the Industrial business, offset by a slightly weaker performance in Medical.

Against a weaker comparative, Q1 revenue of £78.7m was 41% ahead of the prior year period (Q1 2017: £55.7m), with Q1 Group sales volume of 1,051 tonnes being 30% ahead of the prior year (Q1 2017: 810 tonnes).

Alongside continuing strength in Industrial, the Group's Q1 performance also reflects three specific items which were not in the comparative period. These are the benefit from currency hedges taken on at the most favourable post-Brexit rates; sales from our Zyex acquisition; and a sizeable proportion of volumes for the large Consumer Electronics order, compared to negligible volumes in Q1 2017. Excluding these items, our underlying momentum is broadly unchanged from the positive performance we saw in the second half of 2017.

Victrex saw good performances across most end markets, with Electronics being the strongest performer and a steady start in Aerospace. Medical saw a weaker end to the quarter, although we continue to see progress in our innovative PEEK-OPTIMATM HA Enhanced product for the Spine market and outside the US.

Our pipeline of new products remains strong. We have now started supplying the first parts for our Gears mega-programme to a major European car manufacturer, whilst in Magma, a deployment of a 2.5km flowline by Tullow Oil in West Africa supports our expectations of growth this year.

Victrex retains a highly cash generative business model, with no change to its financial position since 30 September 2017. Currency remains supportive for 2018, with the most favourable currency rates coming through in the first half and a heavy bias towards Q1. Looking further ahead, Sterling's re-rating currently implies an increasing headwind for 2019.

Outlook

Jakob Sigurdsson, Chief Executive of Victrex, said: "Victrex has made a strong start to 2018. If the strength in our Industrial business continues to offset weakness in Medical, it could offer a limited degree of upside potential to expectations, although it remains very early in the year and our underlying momentum is broadly unchanged from the second half of 2017.

"Our priorities for 2018 are to remain focused on driving growth, on cost efficiency and to show further progress in our Polymer & Parts strategy."

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations & Corporate Communications +44 (0) 7809 595831

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

Jakob Sigurdsson, Chief Executive +44 (0) 1253 897700

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy, Electronics and Medical. Every day, millions of people rely on products or applications which contain our materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, and drive value for our shareholders. Find out more at www.victrexplc.com

 

Analyst and investor call:

A conference call for analysts and investors will be held this morning at 08.30am GMT. Dial in details +44 (0) 3333 000804 PIN: 22224538#

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSSFFMAFASEDE
Date   Source Headline
29th May 202611:00 amRNSTotal Voting Rights
18th May 20268:50 amRNSDirectorate change
11th May 20267:00 amRNSHalf-year Financial Report
30th Apr 202610:46 amRNSTotal Voting Rights
29th Apr 20264:28 pmRNSHolding(s) in Company
31st Mar 20261:37 pmRNSTotal Voting Rights
24th Mar 20264:29 pmRNSHolding(s) in Company
24th Mar 20262:03 pmRNSHolding(s) in Company
20th Mar 20269:38 amRNSHolding(s) in Company
27th Feb 20262:40 pmRNSTotal Voting Rights
27th Feb 20261:02 pmRNSHolding(s) in Company
24th Feb 202611:41 amRNSHolding(s) in Company
17th Feb 20263:06 pmRNSDirector/PDMR Shareholding
12th Feb 20263:26 pmRNSDirector/PDMR Shareholding
12th Feb 20263:22 pmRNSDirector/PDMR Shareholding
10th Feb 20262:43 pmRNSDirector/PDMR Shareholding
10th Feb 20269:00 amRNSDirectorate change
6th Feb 20261:33 pmRNSResult of AGM
6th Feb 20267:00 amRNSQ1 Trading Update
30th Jan 202611:49 amRNSTotal Voting Rights
28th Jan 202612:25 pmRNSHolding(s) in Company
22nd Jan 202610:21 amRNSHolding(s) in Company
20th Jan 20261:26 pmRNSAdditional Listing
31st Dec 20259:00 amRNSTotal Voting Rights
31st Dec 20259:00 amRNSTotal Voting Rights
22nd Dec 202512:00 pmRNSAnnual Financial Report
22nd Dec 202512:00 pmRNSAnnual Financial Report
18th Dec 202511:49 amRNSDirector/PDMR Shareholding - Replacement
17th Dec 20253:42 pmRNSDirector/PDMR Shareholding
17th Dec 202512:08 pmRNSDirector/PDMR Shareholding
15th Dec 20259:00 amRNSDirector/PDMR Shareholding
11th Dec 20258:52 amRNSDirector/PDMR Shareholding
5th Dec 20259:30 amRNSShare purchase by incoming Director (incoming CEO)
4th Dec 20259:06 amRNSFinancial Calendar Update
2nd Dec 20257:00 amRNSPreliminary Results
1st Dec 202510:49 amRNSBlock listing Interim Review
28th Nov 20259:27 amRNSTotal Voting Rights
20th Nov 20259:05 amRNSAdditional Listing
7th Nov 202510:39 amRNSHolding(s) in Company
31st Oct 20258:58 amRNSTotal Voting Rights
21st Oct 20257:30 amRNSCEO Succession update
3rd Oct 202511:36 amRNSHolding(s) in Company
3rd Oct 20259:03 amRNSHolding(s) in Company
30th Sep 20259:54 amRNSTotal Voting Rights
29th Aug 202510:16 amRNSTotal Voting Rights
31st Jul 20259:14 amRNSTotal Voting Rights
9th Jul 20251:02 pmRNSHolding(s) in Company
8th Jul 20253:33 pmRNSDirector/PDMR Shareholding
8th Jul 20257:00 amRNSDirectorate change: CEO succession
8th Jul 20257:00 amRNSQ3 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.